✦ LIBER ✦

P2.108 Improvements in symptom severity and daily living with saflnamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

✍ Scribed by J. Szasz; R. Borgohain; M. Bhatt; S. Rossetti; V. Lucini; R. Anand

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P2.098 Saflnamide as an adjunct to levod

✍ R. Borgohain; J. Szasz; M. Bhatt; S. Rossetti; V. Lucini; R. Anand 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P2.204 A randomized, double-blind, place

✍ P. Chan; Z. Qin; Z. Zheng; L. Zhang; X. Fang; F. Sun; Z. Gu; S. Chen; J. Ma; C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 65 KB

A phase III double-blind randomized plac

✍ E.F Lartigau; J Giralt; P Glassman; A Lawton; R von Roemeling 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 20 KB

Ustekinumab significantly improves sympt

✍ Richard G. Langley; Steven R. Feldman; Chenglong Han; Brad Schenkel; Philippe Sz 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 415 KB

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONT

✍ Cummings, Jeffrey; Cho, William; Ward, Michael; Friesenhahn, Michel; Brunstein, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Efficacy, safety, and tolerability of du

✍ Hee Chul Eun; Oh Sang Kwon; Je Ho Yeon; Hyo Seung Shin; Byung Yoon Kim; Byung In 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 555 KB